Comparative Pharmacology
Head-to-head clinical analysis: MECLAN versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLAN versus TETRACYN.
MECLAN vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic